Drug Trial Radar · NCT07688772
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
220
Actual
Start
Aug 11, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SHR-1819 injection in patients with Seasonal Allergic Rhinitis (SAR).
Conditions
- Seasonal Allergic Rhinitis
Interventions
SHR-1819 InjectionDrug
SHR-1819 injection.
SHR-1819 Injection PlaceboDrug
SHR-1819 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in the daily reflective Total Nasal Symptom Score (rTNSS) within 2 weeks of treatment.Time frame: 2 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.